Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAbzena Regulatory News (ABZA)

  • There is currently no data for ABZA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

1 Jun 2015 07:00

RNS Number : 4861O
Abzena PLC
01 June 2015
 

ABZENA PLC

("Abzena", the "Company" or the "Group")

Notice of Preliminary Results for the 12 Months Ended 31 March 2015

1 June 2015

Cambridge, UK - Abzena plc (AIM: ABZA), the life sciences company providing services and technologies that enable the development of better biopharmaceutical products, will announce its preliminary results for the 12 months ended 31 March 2015 on Monday, 8 June 2015.

John Burt, CEO of Abzena, and Julian Smith, CFO, will host a presentation for analysts at 9:00am on the morning of the results at the offices of Citigate Dewe Rogerson, 3 London Wall Buildings, London Wall, London EC2M 5SY.

About Abzena

Abzena provides proprietary technologies and complementary services to enable the development of better biopharmaceuticals. The Group comprises PolyTherics and Antitope which have established a broad suite of services and technologies that are designed to improve the chances of successful development of antibodies and proteins with enhanced therapeutic benefits.

Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.

PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimization of the therapeutic properties of biopharmaceuticals.

The Group has built a global customer base over the past decade which includes the majority of the top 20 biopharmaceutical companies, many large and small biotech companies, and academic groups.

Abzena is quoted on the AIM segment of the London Stock Exchange under the symbol ABZA.

www.abzena.com 

 

For more information, please contact:

 

John Burt (Chief Executive Officer)

Julian Smith (Chief Financial Officer)

Abzena plc

Tel: +44 (0)1223 903498

Email: john.burt@abzena.com or julian.smith@abzena.com

 

Christopher Golden and Bobbie Hilliam

Cenkos Securities (Nominated Adviser and Broker)

Tel: +44 (0)20 7397 8900

 

Mark Swallow, Chris Gardner or Pip Batty

Citigate Dewe Rogerson (Corporate and Financial PR)

Tel: +44 (0)20 7638 9571

Email: abzena@citigatedr.co.uk

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORDMGZKRRRGKZG
Date   Source Headline
11th Apr 20173:06 pmRNSDirector/PDMR Shareholding
7th Apr 20171:36 pmRNSGrant of options
5th Apr 20173:45 pmRNSResult of bookbuild
5th Apr 20177:00 amRNSProposed Placing of £25m
6th Mar 20177:00 amRNS'Abzena inside' product enters Phase II trial
3rd Mar 20177:00 amRNSPartner Halozyme to present poster at AACR
1st Mar 20177:00 amRNSMRC grant awarded to collaboration group
21st Feb 20177:01 amRNSAntibody manufacturing development agreement
21st Feb 20177:00 amRNSTrading and business update
8th Feb 20178:43 amEQSEdison issues outlook on Abzena
6th Feb 201710:55 amRNSTotal Voting Rights
31st Jan 201712:53 pmRNSHardman Research: ThioBridge deal update
24th Jan 20177:00 amRNSIssue of Equity
20th Jan 20177:00 amRNSThioBridge license agreement
9th Jan 20179:37 amRNSBlocklisting update
22nd Dec 20167:00 amRNSLicence agreement
13th Dec 20167:15 amRNSHardman Research: Opening new doors
30th Nov 20167:00 amRNSHalf year results
23rd Nov 20168:09 amRNS'Abzena inside' product study data to be presented
15th Nov 201612:42 pmRNSNotice of half year results
2nd Nov 20167:00 amRNSLicensed product candidate update
24th Oct 20167:00 amRNSSenior Executive Appointments
21st Oct 20167:00 amRNSLicensed product candidate update
22nd Sep 20169:30 amRNSLicensed product candidate update
19th Sep 20162:28 pmRNSChange of Nominated Adviser and Broker
14th Sep 20163:58 pmRNSEdison issues research update on Abzena (ABZA)
13th Sep 20163:41 pmRNSResult of AGM
13th Sep 20167:00 amRNSDirectorate Change
13th Sep 20167:00 amRNSAGM Business Update
16th Aug 201612:20 pmRNSDirector/PDMR Shareholding and Exercise of Options
9th Aug 20162:30 pmRNSNotice of AGM
28th Jul 201611:45 amRNSEdison issues research update on Abzena (ABZA)
25th Jul 20167:00 amRNSManufacturing agreement
14th Jul 201610:37 amRNSJoint venture with Baylor Research Institute
6th Jul 20163:58 pmRNSBlock Listing Update
27th Jun 20164:46 pmRNSDirector Dealings
24th Jun 20169:45 amRNSExercise of warrants
22nd Jun 201610:12 amRNSEdison issues research review on Abzena (ABZA)
15th Jun 20164:09 pmRNSAnnual Report and Accounts
14th Jun 20167:00 amRNSFull year results
26th May 20167:00 amRNSNotice of Results
5th Apr 20169:20 amRNSExercise of Employee Share Options
1st Apr 20169:48 amRNSExercise of Share Options and Director Dealings
16th Mar 20169:45 amRNSExercise of Employee Share Options
9th Mar 201612:47 pmRNSExercise of Employee Share Options
9th Mar 20167:00 amRNSBusiness update
8th Feb 20163:14 pmRNSExercise of employee share options
4th Feb 20162:33 pmRNSHolding(s) in Company
25th Jan 20167:00 amRNSSignificant licence deal for ThioBridgeT
18th Jan 20167:00 amRNSAntitope collaboration awarded European grant

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.